Imagine picking up a gallon of milk and participating in a clinical trial while you’re at it.

That’s the future that CVS Health has dreamed up, and it could soon be a possibility as the company rolls out its new clinical trial services. While not technically a CRO, CVS Health plans to partner with them and drugmakers to recruit patients, run trials, and collect real-world data.

“Our focus is to give the patient or potential research participant choice,” Owen Garrick, VP of conduct and clinical trial services, told Endpoints News. “If we look at the assets and capabilities and history of CVS Health, we have the ability to essentially meet the patient where they are.”

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Over the past 22 years, Aindrea Campbell has worked with just two corporate giants, Ford Motor Company and Apple, with generations of experience between them. But in her new role as Zymergen’s chief manufacturing officer, Campbell comes to a company with years — eight — of history, not decades.

This month, Campbell joined synthetic biology player Zymergen to lead manufacturing for the company’s “biofacturing” process, which ferments genetically engineered molecules to create products that can be used in a range of potential applications, including electronics, consumer health and agriculture, just to name a few. The process, Zymergen says, obviates the need for toxic chemicals and huge infrastructure demands in traditional manufacturing, potentially cutting costs by 90% in half the time.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Amid a flurry of expansion activity, CDMO Lonza is continuing to beef up its manufacturing plants both in its native Switzerland and in the US. The newest plan? A $935 million outlay to build new sites in Visp and Portsmouth, NH, to help grow the company’s biologics portfolio.

The Swiss plant — which will absorb the vast majority of the new funds — will house six 20,000-liter bioreactors as part of a 90,000-plus-square-foot footprint. The site will be designed to optimize energy and water efficiency and cost about $714 million, Lonza said.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

Riding a wave from its work on the Covid-19 response, CDMO giant Catalent has been expanding rapidly in next-gen cell therapies as it gets prepped for a future boom. After a couple of snap expansions at its Belgian campus, Catalent is now adding another facility at the site as part of its plan to bolster its EU hub.

Catalent has acquired Promethera’s Hepatic Cell Therapy Support SA subsidiary and its 32,40-square-foot facility in Gosselies, Belgium, part of the New Jersey drugmaker’s continued expansion plans in the country, the companies said Thursday.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN

As Samsung Biologics looks to dramatically scale its production with a $2 billion “super plant” in Incheon, South Korea, it’s signing on partners to fill its manufacturing schedule. Now, Samsung and TG Therapeutics will work together on manufacturing MS hopeful ublituximab.

“With the recent positive ULTIMATE I and II MS Phase 3 studies, we re-evaluated our supply needs and were very pleased we were able to secure the long-term capacity we believe we will need to meet the potential global demand for ublituximab,” TG CEO Michael Weiss said in a statement. “This is an important next step in our long-standing relationship with Samsung.”

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP LOG IN